BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells

Nature Immunology

Volumn 6, Issue 10, 2005, Pages 1054-1060

  Phan, Ryan T ^a,b,c   Saito, Masumichi ^a   Basso, Katia ^a   Niu, Huifeng ^a,b   Dalla Favera, Riccardo ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA; PROTEIN BCL 6; TRANSCRIPTION FACTOR;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BINDING SITE; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; DNA BINDING; DNA SEQUENCE; GENETIC TRANSCRIPTION; GERMINAL CENTER; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION;

B-LYMPHOCYTES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; ENZYME INHIBITORS; GERMINAL CENTER; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-6; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; ZINC FINGERS;

EID: 27144462049     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/ni1245     Document Type: Article

References (50)

1. Ye, B.H. et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262, 747-750 (1993).
2. Chang, C.C., Ye, B.H., Chaganti, R.S. & Dalla-Favera, R. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc. Natl. Acad. Sci. USA 93, 6947-6952 (1996).
3. Seyfert, V.L., Allman, D., He, Y. & Staudt, L.M. Transcriptional repression by the protooncogene BCL-6. Oncogene 12, 2331-2342 (1996).
4. Dhordain, P. et al. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc. Natl. Acad. Sci. USA 94, 10762-10767 (1997).
5. Wong, C.W. & Privalsky, M.L. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARα, and BCL-6. J. Biol. Chem. 273, 27695-27702 (1998).
6. Fujita, N. et al. MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 119, 75-86 (2004).
7. Pasqualucci, L. et al. Molecular pathogenesis of non-Hodgkin's lymphoma: The role of Bcl-6. Leuk. Lymphoma 44, S5-12 (2003).
8. Cattoretti, G. et al. BCL-6 protein is expressed in germinal-center B cells. Blood 86, 45-53 (1995).
9. Allman, D. et al. BCL-6 expression during B-cell activation. Blood 87, 5257-5268 (1996).
10. MacLennan, I.C. Germinal centers. Annu. Rev. Immunol. 12, 117-139 (1994).
11. Rajewsky, K. Clonal selection and learning in the antibody system. Nature 381, 751-758 (1996).
12. Ye, B.H. et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat. Genet. 16, 161-170 (1997).
13. Dent, A.L., Shaffer, A.L., Yu, X., Allman, D. & Staudt, L.M. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 276, 589-592 (1997).
14. Niu, H., Ye, B.H. & Dalla-Favera, R. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev. 12, 1953-1961 (1998).
15. Bereshchenko, O.R., Gu, W. & Dalla-Favera, R. Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet. 32, 606-613 (2002).
16. Tunyaplin, C. et al. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J. Immunol. 173, 1158-1165 (2004).
17. Fearon, D.T., Manders, P.M. & Wagner, S.D. Bcl-6 uncouples B lymphocyte proliferation from differentiation. Adv. Exp. Med. Biol. 512 21-28 (2002).
18. Lo Coco, F. et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 83, 1757-1759 (1994).
19. Ye, B.H. et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in 8 cell lymphoma. EMBO J. 14, 6209-6217 (1995).
20. Chen, W., Iida, S., Louie, D.C., Dalla-Favera, R. & Chaganti, R.S. Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation. Blood 91, 603-607 (1998).
21. Shen, H.M., Peters, A., Baron, B., Zhu, X. & Storb, U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 280, 1750-1752 (1998).
22. Pasqualucci, L. et al. BCL-6 mutations in normal germinal center B cells: Evidence of somatic hypermutation acting outside Ig loci. Proc. Natl. Acad. Sci. USA 95, 11816-11821 (1998).
23. Migliazza, A. et al. Frequent somatic hypermutation of the 5′ noncoding region of the BCL6 gene in B-cell lymphoma. Proc. Natl. Acad. Sci. USA 92, 12520-12524 (1995).
24. Pasqualucci, L. et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 101, 2914-2923 (2003).
25. Wang, X., Li, Z., Naganuma, A. & Ye, B.H. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. Proc. Natl. Acad. Sci. USA 99, 15018-15023 (2002).
26. Cattoretti, G. et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 7, 445-455 (2005).
27. Shaffer, A.L. et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13, 199-212 (2000).
28. Niu, H., Cattoretti, G. & Dalla-Favera, R. BCL6 controls the expression of the B7-1/CD80 costimulatory receptor in germinal center B cells. J. Exp. Med. 198, 211-221 (2003).
29. Phan, R.T. & Dalla-Favera, R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432, 635-639 (2004).
30. Seoane, J. et al. TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat. Cell Biol. 3, 400-408 (2001).
31. Gaidano, G. et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 88, 5413-5417 (1991).
32. el-Deiry W.S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
33. Yu, J. et al. Identification and classification of p53-regulated genes. Proc. Natl. Acad. Sci. USA 96, 14517-14522 (1999).
34. Seoane, J., Le, H.V. & Massague, J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729-734 (2002).
35. Wu, S. et al. Myc represses differentiation-induced p21 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 22, 351-360 (2003).
36. Herold, S. et al. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol. Cell 10, 509-521 (2002).
37. Klein, U. et al. Transcriptional analysis of the B cell germinal center reaction. Proc. Natl. Acad. Sci. USA 100, 2639-2644 (2003).
38. Shaffer, A.L. et al. Signatures of the immune response. Immunity 15, 375-385 (2001).
39. Allday, M.J., Inman, G.J., Crawford, D.H. & Farrell, P.J. DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J. 14, 4994-5005 (1995).
40. 2/M checkpoint. Genes Dev. 14, 1584-1588 (2000).
41. Wanzel, M. et al. Akt and 14-3-3eta regulate Miz1 to control cell-cycle arrest after DNA damage. Nat. Cell Biol. 7, 30-41 (2005).
42. Sheikh, M.S. et al. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: Role of p53-dependent and independent signal transduction pathways. Oncogene 9, 3407-3415 (1994).
43. Tang, D. et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J. Biol. Chem. 277, 12710-12717 (2002).
44. Staller, P. et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat. Cell Biol. 3, 392-399 (2001).
45. Seoane, J., Le, H.V., Shen, L., Anderson, S.A. & Massague, J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117 211-223 (2004).
46. Papavasiliou, F.N. & Schatz, D.G. Cell-cycle-regulated DNA double-stranded breaks in somatic hypermutation of immunoglobulin genes. Nature 408, 216-221 (2000).
47. Sale, J.E. & Neuberger, M.S. TdT-accessible breaks are scattered over the immunoglobulin V domain in a constitutively hypermutating B cell line. Immunity 9, 859-869 (1998).
48. Bross, L. et al. DNA double-strand breaks in immunoglobulin genes undergoing somatic hypermutation. Immunity 13, 589-597 (2000).
49. Offit, K. et al. BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma. Leuk. Lymphoma 20 85-89 (1995).
50. Polo, J.M. et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat. Med. 10, 1329-1335 (2004).